The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
MOXONIDINE LAPL, MOXONIDINE GENERICHEALTH, MOXONIDINE GH (Lupin Australia Pty Limited)
Product name
MOXONIDINE LAPL, MOXONIDINE GENERICHEALTH, MOXONIDINE GH
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
150 working days (255)
Active ingredients
Moxonidine
Registration type
New generic medicine
Indication
MOXONIDINE LAPL, MOXONIDINE GENERICHEALTH, MOXONIDINE GH (tablets) is indicated for the treatment of hypertension.